logo

BLRX

BioLineRx·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

BLRX fundamentals

BioLineRx (BLRX) released its earnings on Nov 24, 2025: revenue was 427.00K (YoY -91.36%), missed estimates; EPS was 0 (YoY +100.00%), beat estimates.
Revenue / YoY
427.00K
-91.36%
EPS / YoY
0
+100.00%
Report date
Nov 24, 2025
BLRX Earnings Call Summary for Q3,2025
  • JV glioblastoma drug targets $3.7B market; sickle cell trial shows 3x yield; cash funds 2027.
EPS
Revenue

Revenue & Expenses

BLRX has released its 2025 Q3 earnings report, with revenue of 427.00K, reflecting a YoY change of -91.36%, and net profit of -977.00K, showing a YoY change of 83.22%. The Sankey diagram below clearly presents BLRX's revenue sources and cost distribution.

Key Indicators

BioLineRx (BLRX) key financial stats and ratios, covering profitability, financial health, and leverage.
BioLineRx (BLRX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
BioLineRx (BLRX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
BioLineRx (BLRX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does BioLineRx (BLRX) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track BioLineRx (BLRX) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield